Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label lesion size. Show all posts
Showing posts with label lesion size. Show all posts

Wednesday, March 18, 2026

Timing-Dependent Cleavage of Interleukin-1 Receptor Antagonist by Alteplase Impairs Neuroprotection in Ischemic Stroke

 Will your competent? doctor and hospital do anything with this? Or is head in the sand their response? I'd start asking now so enough time is available to get some competency in your hospital!

Timing-Dependent Cleavage of Interleukin-1 Receptor Antagonist by Alteplase Impairs Neuroprotection in Ischemic Stroke



Abstract

BACKGROUND:

Inflammation contributes significantly to neuronal damage in ischemic stroke, with IL (interleukin)-1 being a key mediator. IL-1Ra (IL-1 receptor antagonist) inhibits IL-1 signaling, successfully reducing inflammation in preclinical and clinical stroke studies. However, in the latest phase II trial of IL-1Ra in ischemic stroke (SCIL-STROKE [Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke]), a secondary mediation analysis uncovered an alternative pathway leading to no overall functional benefit. This was the first IL-1Ra trial where participants (73%) received preceding tPA (tissue-type plasminogen activator), raising the possibility that IL-1Ra and tPA interact negatively in ischemic stroke. We aim to explore this postulated negative interaction.

METHODS:

A retrospective analysis of SCIL-STROKE trial data was performed. Next, we used a thromboembolic model of stroke in male wild-type mice (25–35 g; n=10–13), treated with tPA (10 mg/kg, 20–60 minutes poststroke), followed by IL-1Ra (100 mg/kg) either 6 doses, twice daily (after tPA), or 2 doses at 30 minutes (during tPA) and 3 hours poststroke. The primary outcome was lesion volume at 72 hours, measured by T2-magnetic resonance imaging.

RESULTS:

Reanalysis of SCIL-STROKE data revealed a 35.8% reduction in plasma IL-1Ra in patients cotreated with preceding tPA, suggesting IL-1Ra degradation. Biochemical assays confirmed IL-1Ra cleavage by plasmin. While replicating the SCIL-STROKE dosing regimen preclinically, no negative interactions were noted. However, when IL-1Ra was administered during thrombolysis, it impaired the beneficial effect of tPA, reducing lesion volume by only 15%, compared with 68% with tPA alone. Acute cotreatment of IL-1Ra and tPA also led to reduced tissue perfusion and increased leukocyte infiltration and neutrophil extracellular traps.

CONCLUSIONS:

We show that IL-1Ra is cleaved by plasmin, and its administration during thrombolysis worsens outcomes poststroke. These studies confirm a negative interaction between the 2 drugs, which can be prevented by tPA preceding IL-1Ra treatment. The findings raise broader concerns about how tPA may interfere with other neuroprotective treatments.

Graphical Abstract

Get full access to this article

Friday, November 8, 2024

Early imaging correlates of subsequent motor recovery after stroke

 Well, lesion volume from the initial CT or MRI scan completely misses the continuing death of neurons from the 5 causes of the neuronal cascade of death in the first week thus killing off millions to billions of neurons!

Does anyone in stroke actually think?

Early imaging correlates of subsequent motor recovery after stroke

Randolph S Marshall, MS, MD, Eric Zarahn, PhD, Leeor Alon, MS, Brandon Minzer, MS, Ronald M Lazar, PhD, and John W Krakauer, MD Department of Neurology, Columbia University Medical Center, New York 

INTRODUCTION 


There is unexplained variability in the extent to which patients recover after stroke, particularly from the reference point of the first few days after onset. Among studies tracking motor impairment and recovery, only 30–50% of the variance of recovery is explained by the most commonly reported predictors --lesion volume and initial stroke severity 1 , 2. We hypothesized that functional imaging early after stroke could provide information over and above initial severity and lesion volume about the degree of subsequent recovery. Several prior functional imaging studies have reported altered brain activation patterns in patients at various stages of motor recovery after stroke3 6. These studies describe brain activation related to concurrent recovered performance at the time of scanning that differs to varying degrees from what is seen in age-matched controls. In this study we used functional imaging to ask a specific and unique question about motor recovery after stroke: can functional imaging in the early period after stroke detect brain activation related to subsequent recovered performance? Should such activation be identified then it could serve as a physiological target for intervention (e.g. non-invasive brain stimulation) in this early time period. To investigate whether brain activation early after stroke can be correlated with subsequent recovery, we scanned patients approximately 48 hours after stroke using fMRI, and defined recovery as the change in motor impairment from the time of scanning to a follow up point 3 months later. We used 3 different statistical tests: 1) a multivariate test, which is most sensitive to spatially diffuse activation, 2) voxel-wise statistical parametric mapping (SPM), which is most sensitive to focal activation, and 3) primary motor cortex (M1) region of interest (ROI) analysis, which is most sensitive to average activation within this region. The ROI analysis was chosen to test existing hypotheses implicating M1 and the corticospinal tract in recovery.7 9 All tests controlled for lesion volume and initial stroke severity, as well as other established clinical variables. METHODS Subjects We recruited stroke patients from a large screening data base of all patients with the diagnosis of ischemic stroke admitted to Columbia University Medical Center between December, 2004 and April, 2007 (n=993), part of Columbia’s Specialized Program of Translational Research in Acute Stroke (SPOTRIAS), an NINDS-funded national network to investigate new pathophysiologic, diagnostic and clinical approaches in acute stroke. Thirty-three consecutive patients with first ever ischemic stroke and hemiparesis able to undergo fMRI within 48 hours of stroke onset were recruited. Five patients were eligible but refused the fMRI scan. Three underwent the fMRI, but did not complete the 3-month clinical follow up (1 developed dementia, 1 left the country, 1 was incarcerated). Two patients had recurrent stroke prior to the 3-month follow-up and were excluded from analysis. The final sample size of 23 was considered adequate for a functional imaging study of this type. Patients with aphasia or hemineglect alone were not included in this analysis. See Table 1 for more demographic and clinical details. All patients except for 4 underwent a single session of fMRI scanning at our target of 24–48 hours after stroke onset (the remaining 4 patients had their scans between 49 and 96 hours due to scheduling delays; mean time to scan=47.8±21.6h, median=46h). Exclusion criteria also included seizure at stroke onset, moderate to severe aphasia or other cognitive impairment that precluded training on the fMRI task, or any contraindication to MRI. None of the patients had neglect or apraxia on examination. Patients did not smoke on the day of scanning (they were inpatients); caffeine intake was not recorded. The strict eligibility criteria permitted us to control for unwanted variables while preserving the wide spectrum of initial motor severity that would contribute to the correlation analysis. Total lesion volumes were estimated by summing the volumes of the DWI lesion in each slice (length by width by slice thickness measured with the measurement tool in the PACS system software) in which the DWI was positive. Recovery measure Motor impairment was measured with the upper limb Fugl-Meyer assessment (FM)11, which has a maximum score of 66, and is valid and highly reliable over a wide spectrum of severities.12 16 FM was assessed on the day of scanning (FM initial ) and again at 3 months (FM 3 months ). Recovery (ΔFM) was defined as ΔFM = FM 3 months FM initial . Our decision to use a change score as our measure of recovery was based on the idea that the degree of change, rather than the final level achieved, would better reflect a biological recovery process 17. In addition to the FM we also measured hand dynamometry at baseline on the day of scanning (DYN initial ). The reason for doing so was that hand dynamometry score should presumably correlate with the degree of difficulty subjects would have to perform the fMRI hand closure task. DYN initial was taken as an average of 3 measurements of maximal grip force. fMRI data acquisition Patients underwent gradient echo-echoplanar fMRI (GE 1.5 T, 64 × 64 matrix, FOV = 19 cm, 21 slices, slice thickness/skip = 4.5 mm/0 mm, TR = 4000 ms, TE = 52 ms, flip angle = 60°) while performing the repetitive hand closure task described below. One session (40 volumes) was performed per hand. The order in which the hands (affected/unaffected) were tested was counterbalanced across patients except for those with complete plegia (see below). Motor task used during fMRI The task was a simple repetitive hand closure in synchrony with a 1 Hz metronome click, following a block design: 20-second rest epochs alternating with 20-second task epochs (4 cycles total per hand). The instruction was: ”Close your hand gently in rhythm with the click you hear. Start and stop when you hear the instructions through the headphones.” The metronome click was played continuously via MRI-compatible headphones in the scanner. Marshall et al. Page 2 Ann Neurol. Author manuscript; available in PMC 2010 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript

Friday, March 18, 2022

Pre-treatment lesional volume in older stroke patients treated with endovascular treatment

Don't tell us lesional volume tells us poor functional outcome. Solve the fucking problem and prevent that poor functional outcome.

Pre-treatment lesional volume in older stroke patients treated with endovascular treatment

First Published February 28, 2022 Research Article 

Recent studies in the general stroke population treated with endovascular treatment (EVT) reported that higher pre-treatment lesional volumes were independently associated with poor neurological outcome and functional dependence after stroke. However, it has been not evaluated in older patients.

We test the association between the pre-treatment lesional volume on diffusion-weighted magnetic resonance imaging and relevant outcome measures in older adults with stroke treated with EVT.

We included consecutive older adults with stroke (⩾80 years old) treated with EVT in two academic comprehensive stroke centers. The association between pre-treatment lesional volume and relevant outcome measures (poor outcome (modified Rankin scale 4–6), 3-month mortality and symptomatic intracerebral hemorrhage (sICH)) was evaluated using univariate and multivariable models.

Five hundred seventy-nine patients were included (mean age: 85.6 ± 4.1, median lesional volume was 10 ml; interquartile range: 3–30 ml). Pre-treatment lesional volume was associated with poor functional outcome (adjusted odds ratio (aOR): 1.87, 95% confidence interval (CI): 1.60–2.20, for +1 logarithmic increase of lesional volume), 3-month mortality (aOR: 1.50, CI: 1.28–1.76), and sICH (aOR: 1.67, CI: 1.27–2.20). A threshold lesional volume >35 ml predicted 90% of patients with poor functional outcome and a cut-off >51 ml predicted 90% of patients dead at 3 months.

Pre-treatment lesional volume might contribute, in association with other relevant clinical features, to the selection of older stroke patients who will benefit from EVT.

 

Thursday, March 3, 2022

Pre-treatment lesional volume in older stroke patients treated with endovascular treatment

 So you described a problem, offered NO SOLUTION. What the fuck good did this research do for solving all the problems in stroke? Ask your mentors why they approved this research and what it was for. 

Pre-treatment lesional volume in older stroke patients treated with endovascular treatment

First Published February 28, 2022 Research Article 

Recent studies in the general stroke population treated with endovascular treatment (EVT) reported that higher pre-treatment lesional volumes were independently associated with poor neurological outcome and functional dependence after stroke. However, it has been not evaluated in older patients.

We test the association between the pre-treatment lesional volume on diffusion-weighted magnetic resonance imaging and relevant outcome measures in older adults with stroke treated with EVT.

We included consecutive older adults with stroke (⩾80 years old) treated with EVT in two academic comprehensive stroke centers. The association between pre-treatment lesional volume and relevant outcome measures (poor outcome (modified Rankin scale 4–6), 3-month mortality and symptomatic intracerebral hemorrhage (sICH)) was evaluated using univariate and multivariable models.

Five hundred seventy-nine patients were included (mean age: 85.6 ± 4.1, median lesional volume was 10 ml; interquartile range: 3–30 ml). Pre-treatment lesional volume was associated with poor functional outcome (adjusted odds ratio (aOR): 1.87, 95% confidence interval (CI): 1.60–2.20, for +1 logarithmic increase of lesional volume), 3-month mortality (aOR: 1.50, CI: 1.28–1.76), and sICH (aOR: 1.67, CI: 1.27–2.20). A threshold lesional volume >35 ml predicted 90% of patients with poor functional outcome and a cut-off >51 ml predicted 90% of patients dead at 3 months.

Pre-treatment lesional volume might contribute, in association with other relevant clinical features, to the selection of older stroke patients who will benefit from EVT.

 

Wednesday, July 8, 2015

Even Small Brain Lesions May Signal Risk

My doctor told me that there were signs that that I'd had previous strokes. Of course he didn't show me them on scans or discuss what could be done for any problems they might cause.  I'm sure that now - 9 years later - that this news won't cause any change to his behavior.
http://www.medpagetoday.com/Neurology/Strokes/52472?xid=nl_mpt_cardiodaily_2015-07-07&eun=g0d3r

Analysis of ARIC data suggests physicians should pay attention to little lesions, too.

 

Even very small cerebrovascular lesions on MRI may tell of a higher risk of stroke and death, researchers found.
In an analysis of data from the Atherosclerosis Risk in Communities (ARIC) study, having lesions smaller than 3 mm was associated with a significantly increased risk of stroke compared with lesion-free scans (HR 3.47, 95% CI 1.86-6.49), Thomas Mosley, PhD, of the University of Mississippi Medical Center, and colleagues reported in the Annals of Internal Medicine.
Advertisement
That association was actually stronger than the twofold increased risk of stroke with larger lesions, the researchers found.
Mosley told MedPage Today that he was surprised by that finding in particular: "Because the small lesions are at the edge of resolution, they're easy to miss and hence there is more noise in the measurement of these small lesions compared with other MRI-derived measurements. I wasn't sure if this noise would perhaps overpower our ability to detect an association with the outcomes, if one existed. This obviously wasn't the case."
While cerebral lesions 3 mm or larger have been associated with stroke, those smaller than 3 mm are typically ignored. But there have been few studies to assess whether these very small lesions may also be related to important clinical outcomes.
To get a better handle on the significance of these smaller lesions, the researchers looked at data from the ARIC study on 1,884 patients with no prior stroke who had MRI data from 1993 to 1995.

More at link.

Sunday, January 27, 2013

Size Doesn’t Matter: Cortical Stroke Lesion Volume is Not Associated with Upper Extremity Motor Impairment and Function in Mild, Chronic, Hemiparesis

Why would you even expect lesion size to make a difference in upper extremity hemiparesis? Its so blatently obvious that you have to look at location.
http://www.archives-pmr.org/article/S0003-9993%2813%2900031-2/abstract

Abstract 

Objective

To determine: (a) the relationship between lesion volume and upper extremity (UE) motor impairment using the UE section of the Fugl-Meyer (FM); and (b) the relationship between lesion volume and UE functional outcomes using the Arm Motor Ability Test (AMAT) Functional Ability (FA) and Time scales.

Design

Secondary, retrospective analysis of randomized controlled trial data

Setting

Not applicable

Participants

139 subjects with chronic stroke (83 males; mean age of all subjects = 56.7 + 11.2 years; mean time since stroke onset = 59.6 + 65.6 months; 90 subjects with right hemiparesis) and stable, active, distal UE movement.

Intervention

Data were collected related to subjects’ lesion volum and UE movement prior to their participation in a multicenter randomized controlled trial.

Main Outcome Measures

The FM and the AMAT.

Results

Neither age nor lesion volume was related to FM performance. The p-value for the regression coefficient of lesion volume was 0.045 in the AMAT FA model and 0.016 in the AMAT Time model. Lesion volume accounted for only an additional 1.7% (AMAT FA) to 3.1% (AMAT Time) of the variability in motor function, and was not clinically meaningful.

Conclusions

Data suggest no relationship between lesion volume and UE impairment, and a small, clinically insignificant relationship between lesion volume and UE motor function. Stroke affects metabolic changes in intact regions, and causes diffuse structural loss in anatomically remote regions from the infarction. These other factors may account for variance in motor outcomes following stroke.